2025 Annual Report

Publication

Genetic Signatures is pleased to share our 2025 Annual Report. The report details the Company’s full financial year results and provides an overview of performance from the Company’s Chair and CEO. Discover our new partnerships and explore the value of syndromic testing for gastrointestinal diseases, highlighted in a compelling case study from a leading UK…

Read More

Welcoming our new CTO

Genetic Signatures is thrilled to welcome our new Chief Technology Officer, Susanne Pedersen, Ph.D. Susanne Pedersen holds a Ph.D. in Molecular Biology and brings over 25 years of experience in oncology and molecular diagnostics. With 13 years leading clinical trial studies from concept to completion, she has a proven track record in building and managing…

Read More

Genetic Signatures 2024 AGM Highlights

agm 2024 thumnail web scaled

Genetic Signatures 2024 AGM, held on 20th of November, warmly farewelled our highly respected and long serving Chair, Dr Nick Samaras, and welcomed Caroline Waldron as Chair. “Caroline Waldron, our incoming Chair, has worked closely with me to facilitate a smooth transition, and on behalf of the Board, I welcome her to the next chapter…

Read More

A warm welcome to Allison Rossiter

welcome allison rossiter tn scaled

Genetic Signatures’ CEO, Allison Rossiter, brings a distinguished career in healthcare. With a proven track record at Roche Diagnostics, she navigated complex strategic challenges to achieve notable success. Ms Rossiter’s vision and leadership will be invaluable to Genetic Signatures as we enter our next phase of growth. She is warmly welcomed by the team! Allison…

Read More

Genetic Signatures Appoints Former Roche Diagnostics Executive Allison Rossiter as CEO

genetic signatures ceo allison rossiter (jun 24) web

Genetic Signatures Limited [ASX:GSS] (“GSS” or the “Company”), a global molecular diagnostics company today announces that its Board of Directors has appointed Allison Rossiter, a highly experienced molecular diagnostics executive, to serve as CEO, based in Sydney, Australia. Ms Rossiter has extensive global experience in the diagnostics industry and since 2003 has held several senior…

Read More

FDA Clears Genetic Signatures’ Molecular Diagnostic Solution for Gastrointestinal Parasites

United States FDA clears Gastrointestinal Parasite Detection kit for sale

A comprehensive and uniquely differentiated multiplex PCR test for gastrointestinal parasites Newtown, New South Wales, Australia, 4th Jun 2024 – Genetic Signatures Limited (ASX: GSS), a leader in molecular diagnostic solutions for infectious disease, announces United States (US) Food and Drug Administration (FDA) 510(k) clearance for its EasyScreen™ Gastrointestinal Parasite Detection Kit and GS1 automated…

Read More

Genetic Signatures farewells long-standing CEO & Director, Dr. John Melki

farewell john melki (30 4 24)

Genetic Signatures shares a bittersweet moment as we bid farewell to Dr. John Melki, who has announced his decision to step down as CEO and Director after an illustrious 21 years of leadership. John possesses an extraordinary blend of qualities and skills that have not only inspired, but also motivated and guided our team through a…

Read More